JP2001515708A - ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用 - Google Patents

ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用

Info

Publication number
JP2001515708A
JP2001515708A JP2000510463A JP2000510463A JP2001515708A JP 2001515708 A JP2001515708 A JP 2001515708A JP 2000510463 A JP2000510463 A JP 2000510463A JP 2000510463 A JP2000510463 A JP 2000510463A JP 2001515708 A JP2001515708 A JP 2001515708A
Authority
JP
Japan
Prior art keywords
antibody
humanized
chain variable
human
variable sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000510463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515708A5 (cg-RX-API-DMAC10.html
Inventor
アメリア ブラック
ネイビル ハンナ
エデュアード エイ パドラン
ローランド エイ ニューマン
Original Assignee
アイデック・ファーマシューティカルズ・コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイデック・ファーマシューティカルズ・コーポレイション filed Critical アイデック・ファーマシューティカルズ・コーポレイション
Publication of JP2001515708A publication Critical patent/JP2001515708A/ja
Publication of JP2001515708A5 publication Critical patent/JP2001515708A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
JP2000510463A 1997-09-08 1998-09-08 ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用 Abandoned JP2001515708A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/925,339 US6440418B1 (en) 1995-11-07 1997-09-08 Methods of treating autoimmune diseases with gp39-specific antibodies
US08/925,339 1997-09-08
PCT/US1998/018163 WO1999012566A1 (en) 1997-09-08 1998-09-08 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF

Publications (2)

Publication Number Publication Date
JP2001515708A true JP2001515708A (ja) 2001-09-25
JP2001515708A5 JP2001515708A5 (cg-RX-API-DMAC10.html) 2006-07-06

Family

ID=25451580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510463A Abandoned JP2001515708A (ja) 1997-09-08 1998-09-08 ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用

Country Status (11)

Country Link
US (3) US6440418B1 (cg-RX-API-DMAC10.html)
EP (1) EP1011725A4 (cg-RX-API-DMAC10.html)
JP (1) JP2001515708A (cg-RX-API-DMAC10.html)
KR (1) KR100574591B1 (cg-RX-API-DMAC10.html)
CN (1) CN1278736A (cg-RX-API-DMAC10.html)
AU (1) AU740981B2 (cg-RX-API-DMAC10.html)
CA (1) CA2302752A1 (cg-RX-API-DMAC10.html)
IL (1) IL134888A0 (cg-RX-API-DMAC10.html)
NO (1) NO20001104L (cg-RX-API-DMAC10.html)
RU (1) RU2207878C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999012566A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528258A (ja) * 2015-07-14 2018-09-27 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
CN1572325A (zh) * 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
CA2223225A1 (en) * 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
US7163686B1 (en) * 1999-05-15 2007-01-16 The Regents Of The University Of California Protein A based binding domains with desirable activities
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
EP1223981B1 (en) * 1999-10-22 2008-01-16 Biogen Idec MA Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003086463A1 (en) * 2002-04-03 2003-10-23 Keio University Remedies for pemphigus containing cd40l antagonist as the active ingredient
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2004074432A2 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
RU2240134C1 (ru) * 2003-02-17 2004-11-20 Козлов Владимир Александрович Способ лечения больных сахарным диабетом
US20050079234A1 (en) * 2003-08-27 2005-04-14 Chiang Yang Chi Compositions comprising herbs and method for immunomodulation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2010003193A1 (en) * 2008-07-11 2010-01-14 Phylogica Limited Peptide inhibitors of cd40l signaling and uses therefor
BRPI1009455A2 (pt) 2009-03-10 2016-03-01 Baylor Res Inst anticorpos anti-c40 e usos dos mesmos
BRPI1009454A2 (pt) 2009-03-10 2019-09-24 Baylor Res Institute vacinas contra o câncer direcionadas a células apresentadoras de antígenos
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
RU2439712C1 (ru) * 2010-07-21 2012-01-10 Сергей Валентинович Логвинов Способ моделирования аутоиммунного оофорита
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2015106281A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
CN115279406A (zh) 2020-01-13 2022-11-01 阿帕特夫研究和发展有限公司 蛋白质治疗剂的调配物
US20240262920A1 (en) 2021-05-21 2024-08-08 Aptevo Research And Development Llc Dosing regimens for protein therapeutics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5092585A (en) 1987-06-11 1992-03-03 Jones Arthur A Apparatus for testing and/or exercising the cervical muscles of the human body
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP2840131B2 (ja) 1993-09-02 1998-12-24 トラスティーズ・オブ・ダートマス・カレッジ 液性免疫の持続性抑制方法
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性t细胞耐受的方法
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
GB9507719D0 (en) * 1995-04-13 1995-05-31 Boc Group Plc Machining of materials
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528258A (ja) * 2015-07-14 2018-09-27 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用
JP2021063129A (ja) * 2015-07-14 2021-04-22 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用
JP2023123812A (ja) * 2015-07-14 2023-09-05 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用
JP7605914B2 (ja) 2015-07-14 2024-12-24 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用
JP2025038055A (ja) * 2015-07-14 2025-03-18 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗cd154抗体ならびにヒト免疫療法での使用

Also Published As

Publication number Publication date
US7122187B2 (en) 2006-10-17
CA2302752A1 (en) 1999-03-18
EP1011725A4 (en) 2005-03-16
KR20010023787A (ko) 2001-03-26
RU2207878C2 (ru) 2003-07-10
NO20001104D0 (no) 2000-03-03
NO20001104L (no) 2000-05-08
WO1999012566A9 (en) 1999-06-03
EP1011725A1 (en) 2000-06-28
US20060153837A1 (en) 2006-07-13
US6440418B1 (en) 2002-08-27
WO1999012566A1 (en) 1999-03-18
KR100574591B1 (ko) 2006-04-28
AU9565298A (en) 1999-03-29
AU740981B2 (en) 2001-11-15
US20030170233A1 (en) 2003-09-11
CN1278736A (zh) 2001-01-03
IL134888A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
AU740981B2 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
US6506383B1 (en) Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies
WO1997017446A9 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
RU2264413C2 (ru) РЕКОМБИНАНТНОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ 1β
JP5782132B2 (ja) 抗CD40抗体のサイレントFc変異体
JP6598844B2 (ja) ヒトカンナビノイド1(cb1)受容体に結合する抗体
EP2289534B1 (en) NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease
ES2307301T3 (es) ANTICUERPO LO-CD2a Y USOS DEL MISMO PARA INHIBIR LA ACTIVACION Y PROLIFERACION DE CELULAS T.
CA2467597A1 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
JP2004529945A (ja) Cd21を阻害する薬剤を使用して抗体媒介性病理を処置する方法
JP2005531282A (ja) 炎症性疾患の治療に用いる抗tirc7抗体
US20030012781A1 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
JPH09502184A (ja) 体液性免疫の持続性抑制方法
WO2025117849A1 (en) Methods and compositions for prevention of transplant rejection
AU2001275224B2 (en) Non-agonistic antibodies to human GP39, compositions containing, and therapeutic use thereof
AU2001275224A1 (en) Non-agonistic antibodies to human GP39, compositions containing, and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060512

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20081107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081107